09.14.26 -- Why Integrated Process Development Delivers Faster, More Scalable Results

High-density perfusion cultivation can support stronger productivity in a smaller footprint. See how integrated cell retention and process control enabled rapid growth in eight days.

The shift from static platforms to adaptive, knowledge-driven development helps teams manage BsAb complexity, accelerate development and improve IND readiness.

Learn how a two-step TIL selection workflow improves manufacturing from cold tumors by enriching tumor-reactive cells earlier, reducing exhausted phenotypes, and supporting stronger expansion.

Researchers are advancing engineered mesenchymal stem cells using efficient non-viral gene delivery, enabling scalable, targeted therapies for solid tumors while preserving tumor-homing function.

Explore temperature effects on product titer, automated cell culture development workflow, maximizing product life-cycle efficiency with the right DOE strategy, and effective data management.

Cloud-based monitoring and analytics help centralize data, gain real-time insight, and improve decision-making. Enhanced visibility and collaboration enable faster optimization and consistency.

Gain insight into how this advanced strategy accelerates development timelines while delivering consistently high titers, robust manufacturability, and enhanced product quality.

Uncover how transposon technology is being reimagined as a precise genetic engineering tool to create high-performing CHO cell lines for biotherapeutic production with enhanced glycan profiles.

Delve into how meticulous purification optimization can maximize recovery and impurity removal by leveraging scalable downstream technologies to meet regulatory and process economy requirements.

A closed, automated centrifuge system achieves consistent cell recovery and viability across leukopak donors and wash media, addressing key limitations of manual cell therapy processing.

Shift from unpredictable cell-line engineering to an enzymatic post-production step. Take a look at how this paradigm shift eliminates biological variability to ensure optimal drug performance.

Neurodegenerative disease research faces a critical gap between symptom management and disease modification, making better preclinical models an urgent priority for the field.